Eligibility for faricimab in a real-world diabetic macular oedema population: a cross-sectional study
Purpose To investigate the eligibility for faricimab in a real-world diabetic macular oedema (DMO) population to the YOSEMITE and RHINE trials, and to compare the eligible DMO populations to the trial populations.Design, settings and participants This retrospective cross-sectional analysis used data...
Saved in:
Main Authors: | Helena Norberg, Inger Westborg, Ayat Al-Najjar |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2025-02-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/15/2/e089801.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Eligibility of Dapagliflozin and Empagliflozin in a Real-World Heart Failure Population
by: Erik Håkansson, et al.
Published: (2021-01-01) -
Clinical Evaluation of Faricimab in Real-World Diabetic Macular Edema in India- A Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2025-01-01) -
Eyes that Do Not Meet the Eligibility Criteria of Clinical Trials on Age-Related Macular Degeneration: Proportion of the Real-World Patient Population and Reasons for Exclusion
by: Jae Hui Kim, et al.
Published: (2021-01-01) -
Inflammation and Macular Oedema after Pars Plana Vitrectomy
by: Vito Romano, et al.
Published: (2013-01-01) -
Macular Oedema in Idiopathic Macular Telangiectasia Type 1 Responsive to Aflibercept but Not Bevacizumab
by: O’Sam Shibeeb, et al.
Published: (2014-01-01)